Prescribing guide
Ultomiris (ravulizumab-cwvz)Meningococcal vaccine requirements, REMS, weight-based dosing, supplemental doses and prior authorization criteria for generalized myasthenia gravisFor prescribers and their offices treating generalized myasthenia gravis: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
REMS-certified prescriber, MenACWY and MenB vaccination completed or updated at least 2 weeks before day 1 or antibacterial prophylaxis with vaccines as soon as possible, counseling with the Patient Safety Card and Patient Guide, and a REMS-certified healthcare setting or pharmacy that verifies prescriber certification and documents vaccination status.
Example PA threshold
Label: adults with gMG who are anti-AChR antibody positive, 40kg or more. FEP example: age 18 or older, positive anti-AChR serology, MGFA class II to IV, baseline MG-ADL 6 or more or QMG above 9, inadequate response, intolerance or contraindication to 1 listed agent, no dual therapy with another C5 complement inhibitor for gMG, meningococcal vaccination at least 2 weeks before initiation unless treatment cannot be delayed, prescriber enrolled in the REMS.
Monitoring
Meningococcal infection at any time, at least 1 hour of observation after each infusion, revaccination per ACIP for the duration of therapy; no scheduled laboratory test is written into the label for gMG.
Support line
Alexion OneSource, 1-888-765-4747, Monday to Friday 8:30 AM to 8 PM ET, CoPay Program as little as $0 for commercial plans, annual maximums may apply, enrollment fax 1-800-420-5150; the label lists the same number for the REMS.
Give your patient their plan
A one-page handout for starting Ultomiris, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/ultomiris-myastheniaBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Certify in the ULTOMIRIS and SOLIRIS REMS | Review the Prescribing Information, Healthcare Provider Safety Brochure, Patient Safety Card and Patient Guide, then submit the Prescriber Enrollment Form to the REMS. | FDA REMS page |
| Assess before initiation | Assess for unresolved meningococcal infection and do not initiate if a serious one is unresolved. Assess vaccination status for serogroups A, C, W, Y and B and vaccinate as needed per current ACIP recommendations for complement inhibitor recipients. | FDA REMS page |
| Vaccinate | Complete or update vaccination against Neisseria meningitidis serogroups A, C, W, Y and B at least 2 weeks before the first dose. ACIP's schedule for these patients differs from the vaccine prescribing information, so prior standard vaccination may not meet it. | FDA label |
| Or prophylaxis | If urgent therapy is indicated in a patient not up to date, give antibacterial prophylaxis and the vaccines as soon as possible; the REMS requires the prescriber to write the prophylaxis prescription. The label says optimal regimens and durations have not been studied. | FDA label |
| Counsel and hand over the card | Counsel with the Patient Safety Card and Patient Guide and give the patient copies. The card is carried at all times during treatment and for 8 months after the last Ultomiris dose. | FDA REMS page |
| Pneumococcal and Hib | Section 5.3 notes increased susceptibility to S. pneumoniae and H. influenzae, higher risk in children, and says to vaccinate against S. pneumoniae and Hib per ACIP; the sentence states no age limit, but it directly follows one about children, and the Medication Guide addresses these vaccines for children. Not a REMS element. | FDA label |
| Book a certified site | Healthcare settings and pharmacies that dispense must be certified. Before each dispense they contact the REMS to verify the prescriber is certified. Before the first dose they assess and document meningococcal vaccination status, including prophylaxis if needed, and repeat that for up to 6 months in patients not initially up to date. | FDA REMS page |
| Contraindication | Do not initiate in a patient with unresolved serious Neisseria meningitidis infection. This is the label's only contraindication. | FDA label |
| OneSource enrollment | Online form, email to OneSource@Alexion.com or fax to 1-800-420-5150, with the patient's signature. The form lists gMG as a condition; interpreters are available. | OneSource enrollment |
| Access tools | Alexion Access Navigator posts a gMG common prior authorization criteria resource, a sample letter of medical necessity, a sample appeal letter, a compendium of gMG references, a coding and billing guide, a reauthorization guide and home infusion access considerations. Field Reimbursement Managers are reached through 1-888-765-4747. | Alexion Access Navigator |
| CoPay Program | Commercial insurance only, enrolled in OneSource, FDA-approved indication, US or territories; as little as $0, annual maximums may apply. Excludes Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD and TRICARE. Massachusetts and Rhode Island residents get medication but not infusion cost help. | CoPay terms |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, July 1, 2026. Approval six months at first, then 12 months at a time on renewal. Renewal asks for a decrease of at least 2 points in the MG-ADL or QMG total score from baseline, no unacceptable toxicity and continued REMS enrollment. This policy was approved on June 11, 2026 and cites the September 2025 label. It predates the October 2026 label, which added IgA nephropathy as a use. The gMG use it describes matches the current label. It still uses the old program name, Ultomiris REMS, from before March 2024. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Generalized myasthenia gravis, age 18 or older | Diagnosis in the note | FEP Blue policy |
| Serology | Positive serologic test for anti-AChR antibodies | Antibody result with date | FEP Blue policy |
| Severity class | MGFA clinical classification class II to IV | MGFA class in the note | FEP Blue policy |
| Baseline score | Documented baseline MG-ADL total score of 6 or more, or QMG total score above 9 | Dated score sheet; renewal is measured against it | FEP Blue policy |
| Prior therapy | Inadequate treatment response, intolerance or contraindication to ONE of: acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide | Agent, dates, and the response, intolerance or contraindication | FEP Blue policy |
| No dual therapy | No dual therapy with another prior authorization C5 complement inhibitor for gMG; Appendix 3 lists Soliris, Ultomiris and Zilbrysq | Medication list; for a switch, the last eculizumab or zilucoplan dose date | FEP Blue policy |
| Vaccination | Vaccination against Neisseria meningitidis at least 2 weeks prior to initiation, unless treatment cannot be delayed | Vaccine names and dates, or the prophylaxis prescription | FEP Blue policy |
| REMS | Prescriber enrolled in the REMS; the policy still uses the old name Ultomiris REMS | Enrollment confirmation | FEP Blue policy |
| Approval duration | Six months initially, 12 months on renewal; the policy cites the September 2025 package insert | Calendar the renewal ahead of the next 8-week dose | FEP Blue policy |
| Renewal | Decrease of MG-ADL or QMG total score from baseline of 2 points or more, absence of unacceptable toxicity, no dual C5 therapy, prescriber still enrolled in the REMS | Current MG-ADL or QMG next to the baseline score | FEP Blue policy |
| Trial population | Study ALXN1210-MG-306 (NCT03920293) randomized 175 complement inhibitor naive adults with MGFA class II to IV and MG-ADL of 6 or more; label section 14.3 adds that all had a positive anti-AChR serologic test | MGFA class and MG-ADL, for a letter of medical necessity | ClinicalTrials.gov |
Ultomiris dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1, loading | 40 to under 60kg: 2,400mg. 60 to under 100kg: 2,700mg. 100kg or more: 3,000mg. Diluted to 50mg/mL in 0.9% sodium chloride, through a 0.2 or 0.22 micron filter; minimum infusion 0.8, 0.6 and 0.4 hours, maximum rate 60, 90 and 150mL/hr respectively. | FDA label |
| Day 15, first maintenance | 3,000mg, 3,300mg or 3,600mg by the same weight bands; minimum infusion 0.9, 0.7 and 0.5 hours, maximum rate 67, 95 and 144mL/hr. The 7-day window does not apply to this dose. | FDA label |
| Every 8 weeks | Maintenance dose every 8 weeks from day 15. Occasional variation within 7 days of the scheduled day is allowed; subsequent doses return to the original schedule. | FDA label |
| Switching from eculizumab | Loading dose at the time of the next scheduled eculizumab dose; first maintenance dose 2 weeks after the loading dose (Table 2). | FDA label |
| After each PE or PP session | Within 4 hours. 40 to under 60kg: 1,200mg if the most recent dose was 2,400mg, 1,500mg if 3,000mg. 60 to under 100kg: 1,500mg if 2,700mg, 1,800mg if 3,300mg. 100kg or more: 1,500mg if 3,000mg, 1,800mg if 3,600mg (Table 3). | FDA label |
| After an IVIg cycle | 600mg within 4 hours following completion of the cycle, for every weight band of 40kg or more (Table 3). Table 6 gives minimum infusion times for supplemental doses, from 0.17 to 0.5 hours. | FDA label |
| Missed dose | The patient should contact the healthcare provider immediately. | FDA label |
| Preparation and stability | Administer immediately after dilution. If not, refrigerate at 2 to 8°C for no more than 24 hours including infusion time, then give within 4 hours of removal. Let the admixture reach room temperature in ambient air only. | FDA label |
| Vials | 300mg/3mL (NDC 25682-025-01) and 1,100mg/11mL (NDC 25682-028-01) single-dose vials, one per carton; refrigerate at 2 to 8°C in the carton, do not freeze or shake. | FDA label |
| Route | Intravenous infusion only, by a healthcare provider. The current label carries no subcutaneous presentation. | FDA label |
| Pediatric and geriatric | Safety and effectiveness in pediatric patients with gMG have not been established. The gMG studies included 54 patients aged 65 or older, too few to determine whether they respond differently. | FDA label |
Monitoring the Ultomiris label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before day 1 | Meningococcal vaccination status against the ACIP complement inhibitor schedule; unresolved serious N. meningitidis infection | Required by the label and the REMS; prophylaxis prescription if urgent; initiation contraindicated with unresolved serious infection | FDA label |
| Each infusion | Infusion-related reactions: lower back or abdominal pain, muscle spasms, drop or rise in blood pressure, rigors, limb discomfort, hypersensitivity, dysgeusia; anaphylaxis reported postmarketing | Observe at least 1 hour after completion; slow or stop at the physician's discretion, interrupt for cardiovascular instability or respiratory compromise. Reported in approximately 1 to 8% across trials | FDA label |
| Any time | Meningococcal infection: fever, fever with tachycardia, headache with fever, confusion, myalgia with flu-like symptoms, fever with rash, headache with nausea or vomiting, headache with stiff neck or back, photophobia | Evaluate immediately; consider interrupting Ultomiris during treatment of serious meningococcal infection, weighing the risk of interruption in the disease being treated | FDA label |
| Per ACIP | Meningococcal revaccination | Revaccinate considering the duration of therapy; vaccination does not eliminate risk | FDA label |
| Ongoing | Other Neisseria and encapsulated bacterial infections, including disseminated gonococcal infection | Use caution with any other systemic infection; counsel on gonorrhea prevention and regular testing for patients at risk | FDA label |
| gMG trial safety | Ultomiris (n=86) against placebo (n=89): diarrhea 15% and 12%, upper respiratory tract infection 14% and 8%, dizziness 9% and 3%, back pain 8% and 6%, abdominal pain 6% and 0, urinary tract infection 6% and 4% | Serious adverse reactions 23% and 16%; serious infections in at least 9% and 4%; one fatal COVID-19 pneumonia on Ultomiris and one infection leading to discontinuation | FDA label |
| gMG trial efficacy | Week 26 LS mean change, Ultomiris and placebo: MG-ADL -3.1 and -1.4, difference -1.6 (95% CI -2.6 to -0.7); QMG -2.8 and -0.8, difference -2.0 (95% CI -3.2 to -0.8); both p below 0.001 | MG-ADL improvement of 3 points or more in 56.7% and 34.1%; QMG improvement of 5 points or more in 30.0% and 11.3% (p = 0.005) | FDA label |
| Immunogenicity | No treatment-emergent antibodies to ravulizumab-cwvz were detected in the gMG study (N=86) | No antibody testing is written into the label | FDA label |
| After stopping | Patient Safety Card carried for 8 months after the last dose; breastfeeding avoided for 8 months after the final dose | The label's discontinuation monitoring periods are written for PNH and aHUS, not gMG | FDA label |
Ultomiris drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Plasma exchange, plasmapheresis, IVIg | Reduce serum ravulizumab concentrations and require a supplemental dose within 4 hours (Table 3) | FDA label |
| Neonatal Fc receptor blockers | Agents such as efgartigimod may lower systemic exposure and reduce effectiveness; closely monitor for reduced effectiveness | FDA label |
| Concomitant gMG therapy | At trial entry over 80% were on acetylcholinesterase inhibitors, 70% on corticosteroids and 68% on non-steroidal immunosuppressants; patients were permitted to continue these throughout the study | FDA label |
| Anticoagulants | Treatment should not alter anticoagulant management | FDA label |
| Pregnancy and lactation | No human data; registry 1-833-793-0563; human IgG crosses the placenta; discontinue breastfeeding during treatment and for 8 months after the final dose | FDA label |
| Contraindicated | Initiation in patients with unresolved serious Neisseria meningitidis infection | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older, a positive AChR antibody test and MGFA class II to IV. It also asks for a baseline MG-ADL score of 6 or more, or a QMG score above 9. Your neurologist's office sends the records that show each of these points.
- The plan asks what you tried firstThe FEP policy asks for an inadequate response, intolerance or contraindication to 1 listed medicine. The list is an acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate and cyclophosphamide. The office documents which one applies to you and why.
- Another C5 inhibitor is on your recordThe FEP policy does not approve Ultomiris together with another C5 complement inhibitor for gMG, and its list names Soliris and Zilbrysq. Your neurologist's office sends the plan your current medicine list.
- Your vaccine dates are missingThe REMS requires the infusion site or pharmacy to check and record your meningococcal vaccine status before the first dose. The fix is the office sending the vaccine dates, or the antibiotic prescription if treatment cannot wait.
- The infusion site is not certifiedOnly healthcare settings and pharmacies certified in the ULTOMIRIS and SOLIRIS REMS may dispense it. The office moves the booking to a certified site, which makes it a routing problem and not a denial.
- The prescriber is not enrolled in the REMSBefore each dispense, the site must contact the REMS to confirm the prescriber is certified. A prescriber enrolls by completing the Prescriber Enrollment Form and sending it to the REMS.
- The plan says no after reviewAlexion Access Navigator posts a gMG sample letter of medical necessity and a sample appeal letter for your neurologist's office. It also posts a guide to peer-to-peer reviews, a step some offices use before a formal appeal.
- A copay you cannot payWith commercial insurance, the OneSource CoPay Program can bring the cost as low as $0 for eligible patients. Medicare, Medicaid and other government plans are excluded, and OneSource says it can connect those patients with third-party resources.
- You live in Massachusetts or Rhode IslandThe CoPay terms say residents of these 2 states can get help with medicine costs but not with infusion costs. OneSource answers questions about the terms at 1-888-765-4747.
- The renewal after 6 monthsThe FEP policy approves 6 months at first, then 12 months at a time. Renewal asks for a drop of at least 2 points in the MG-ADL or QMG score from baseline. Alexion Access Navigator posts a reauthorization guide for offices, so ask the office when the renewal is due.
Alexion OneSource
- The Alexion OneSource CoPay Program for commercial insurance, as little as $0 for Ultomiris for eligible patients
- The CoPay Program covers eligible out-of-pocket medicine and infusion costs, and annual maximums may apply CoPay terms
- CoPay help is not open to Medicare, Medicaid or other federal- or state-funded plans, and OneSource can point those patients to third-party resources
- Residents of Massachusetts and Rhode Island can get help with medicine costs but not infusion costs, under the CoPay terms CoPay terms
- Enrollment online, by email to OneSource@Alexion.com or by fax at 1-800-420-5150, with interpreters available OneSource enrollment
- Questions answered by phone without enrolling OneSource enrollment
- For the neurologist's office, a Field Reimbursement Manager plus gMG sample letters for medical necessity and appeals Alexion Access Navigator
Questions prescribers' offices ask about Ultomiris
What is the Ultomiris dose for generalized myasthenia gravis?
For adults weighing 40kg or more, the October 2026 label gives a weight-based IV loading dose of 2,400mg, 2,700mg or 3,000mg, then a maintenance dose of 3,000mg, 3,300mg or 3,600mg starting 2 weeks later and repeated every 8 weeks. Later doses may occasionally vary within 7 days of the scheduled day, but not the first maintenance dose.
Which vaccines are required before Ultomiris?
Meningococcal vaccines against serogroups A, C, W, Y and B, completed or updated at least 2 weeks before the first dose, per the boxed warning and section 2.2 of the October 2026 label, on the ACIP schedule for complement inhibitor recipients. If urgent therapy is indicated in a patient who is not up to date, the label says to give antibacterial prophylaxis and the vaccines as soon as possible.
What supplemental Ultomiris dose follows plasma exchange or IVIg?
The supplemental dose is 1,200mg to 1,800mg within 4 hours after each plasma exchange or plasmapheresis session, set by weight and the most recent Ultomiris dose, per Table 3 of the October 2026 label. After completion of an IVIg cycle, the supplemental dose is 600mg within 4 hours for every weight band of 40kg or more.
What did the gMG trial in the Ultomiris label show?
A treatment difference of -1.6 points in MG-ADL at week 26 (95% CI -2.6 to -0.7, p below 0.001), with least squares mean changes of -3.1 on Ultomiris and -1.4 on placebo, per section 14.3 of the October 2026 label. QMG changed by -2.8 and -0.8, a difference of -2.0 (95% CI -3.2 to -0.8). The trial randomized 175 adults, 86 to Ultomiris and 89 to placebo.
What do insurers ask for to approve Ultomiris for gMG?
The FEP policy shown here took effect July 1, 2026 and cites the September 2025 label. It asks for age 18 or older, a positive anti-AChR serologic test, MGFA class II to IV, a baseline MG-ADL of 6 or more or QMG above 9, and inadequate response, intolerance or contraindication to 1 listed agent. It also asks for no dual C5 inhibitor therapy, meningococcal vaccination and REMS enrollment, and approves 6 months, then 12 months with a 2-point or greater decrease in MG-ADL or QMG.
Free email alert
Get an email when the Ultomiris label changes
One email the day the FDA revises the Ultomiris prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Ultomiris only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use: prescribing information and Medication Guide, revised 10/2026, SPL version 20, effective October 29, 2026 (openFDA record for DailyMed set ID a9a590d9-0217-43c7-908d-e62a71279791), Alexion Pharmaceuticals, via FDA openFDA, 2026-10-29.
- Approved Risk Evaluation and Mitigation Strategies (REMS): Ultomiris and Soliris, BLA 125166 and BLA 761108, REMS last update 06/01/2026, FDA, 2026-06-01.
- Alexion OneSource™ | ULTOMIRIS | Financial Assistance, Alexion Pharmaceuticals, 2026-11-13.
- Alexion OneSource™ | ULTOMIRIS | Fill Out a Start Form, Alexion Pharmaceuticals, 2026-11-13.
- Alexion OneSource™ CoPay Program Terms and Conditions, US/ALL/1223 V1 12/2024, Alexion Pharmaceuticals, 2026-11-13.
- Alexion Access Navigator | Ultomiris gMG, Alexion Pharmaceuticals, 2026-11-13.
- 5.85.033 Ultomiris (ravulizumab-cwvz), Blue Cross Blue Shield Federal Employee Program, 2026-07-01.
- BLA 761108/S-23 supplement approval letter, generalized myasthenia gravis and Ultomiris REMS modification, FDA, 2022-04-27.
- Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis (NCT03920293, Study ALXN1210-MG-306), ClinicalTrials.gov, 2026-11-13.
A reference drawn from the October 29, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 13, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.